ReviewGut2017
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
Review in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739486 (Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease), which is not on this map. Cited by 566 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
Who cites it
566 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,173 citations in OpenAlex.
- Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review.International journal of molecular sciences · 2025Pooled it
- Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis.Medicine · 2025Pooled it
- Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Association between air pollution and risk of non-alcoholic fatty liver disease: an updated meta-analysis.Frontiers in public health · 2025Pooled it
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Research hotspots and future trends in lipid metabolism in chronic kidney disease: a bibliometric and visualization analysis from 2004 to 2023.Frontiers in pharmacology · 2024Pooled it
- The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial.Journal of translational medicine · 2025Trial
- Comparative effects of aerobic and resistance exercise on bile acid profiles and liver function in patients with non-alcoholic fatty liver disease.BMC gastroenterology · 2025Trial
- Incidence of Cardiovascular Events and Extrahepatic Malignancies in Steatotic Liver Disease Subgroups.Digestive diseases and sciences · 2026Article
- Steatotic liver disease in Latin America: current views and perspectives.Nature reviews. Gastroenterology & hepatology · 2026Review
- Commentary: Diagnostic performance of ultrasound-derived fat fraction for grading hepatic steatosis in patients with chronic liver diseases-a multicenter study.European radiology · 2026Article
- Prevalence, Comorbidities, and Mortality of Obesity Classes 4 and 5 in Adults.Obesity science & practice · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Association between plant-based diet quality and metabolic dysfunction-associated steatotic liver disease (MASLD) among multiethnic adults.European journal of clinical nutrition · 2026Article
- Metabolic dysfunction-associated steatotic liver disease is associated with myocardial ischemia in patients with suspected or known coronary artery disease, especially in patients without obstructive coronary artery disease.BMC medical imaging · 2026Article
- Identification of the critical immune-related drivers shared by non-alcoholic fatty liver disease and osteoporosis.Cellular and molecular life sciences : CMLS · 2026Article
- C-reactive protein-triglyceride glucose index as a predictor of heart failure risk in adults with MASLD: a prospective cohort study.Scientific reports · 2026Article
- Article
- Article
506 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic inflammatory '
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.